TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03965819

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pain Bloc-R
Description: Herbal Supplement containing Vit D3, Vit B6, Vit B12, White Willow Bark, Angelica Root, Acetyl L-carnitine HCl, Caffeine, L-Theanine, Benfotiamine, and L-Tetrahydropalmatine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pain Bloc-R
Description: Herbal Supplement containing Vit D3, Vit B6, Vit B12, White Willow Bark, Angelica Root, Acetyl L-carnitine HCl, Caffeine, L-Theanine, Benfotiamine, and L-Tetrahydropalmatine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pain Bloc-R
Description: Herbal Supplement containing Vit D3, Vit B6, Vit B12, White Willow Bark, Angelica Root, Acetyl L-carnitine HCl, Caffeine, L-Theanine, Benfotiamine, and L-Tetrahydropalmatine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Comparator - Acetaminophen
Description: DIN 02447479 Encapsulated for Blinding Purposes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Comparator - Acetaminophen
Description: DIN 02447479 Encapsulated for Blinding Purposes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Comparator - Acetaminophen
Description: DIN 02447479 Encapsulated for Blinding Purposes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: No active ingredients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: No active ingredients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: No active ingredients
Study: NCT00779584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8776
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8776
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8776
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8776
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8776
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8776
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8776
Description: IV infusion
Study: NCT04685460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images
Description: customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images were used in this study.
Study: NCT01369108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flowable composite
Description: Restoration of small Class V and I cavities in molar and premolar teeth

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional composite restorative
Description: Restoration of small Class V and I cavities in molar and premolar teeth
Study: NCT00779584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8776
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8776
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion
Study: NCT03747770

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent HPV vaccine CERVARIX®
Description: Bivalent HPV vaccine(Glaxo Smith Kline, GSK, Rixensart, Belgium) presented as a suspension for intramuscular injection containing purified viral L1 protein for HPV types 16 and 18. Each 0.5 mL dose of the bivalent vaccine contains 20μg of HPV-16 L1 protein and 20 μg of HPV-18 L1 protein adsorbed onto a proprietary adjuvant system containing 500 μg of aluminum hydroxide and 50 μg of 3-O-desacyl-4-monophosphoryl lipid A (AS04)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent HPV vaccine CERVARIX®
Description: Bivalent HPV vaccine(Glaxo Smith Kline, GSK, Rixensart, Belgium) presented as a suspension for intramuscular injection containing purified viral L1 protein for HPV types 16 and 18. Each 0.5 mL dose of the bivalent vaccine contains 20μg of HPV-16 L1 protein and 20 μg of HPV-18 L1 protein adsorbed onto a proprietary adjuvant system containing 500 μg of aluminum hydroxide and 50 μg of 3-O-desacyl-4-monophosphoryl lipid A (AS04)
Study: NCT02476214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group prenatal care
Description: Intervention group Groups of 8-12 women who are in similar week of pregnancy / due date. The first group session will begin at 12-14 week (depends on gestational age at first OBGYN visit). The group meetings will be held once a month until 28 weeks of pregnancy. From 28 weeks and until the end of pregnancy or 40 weeks, it will be held once every two weeks (according to the Ministry of Health guidelines). The last session will be held approximately 6 weeks after birth.~There will be about 10 group sessions. Each session will be around 90 minutes. At the beginning of every group meeting, the nurse will preform a short anamnesis and measures in private, followed by discussion and guidance. At the end of the session, if needed, women can have private time with the nurse.
Study: NCT01159223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV/r
Description: All participants will be randomized to take ATV/r 200 mg/100 mg OD or ATV/r 300/100 mg OD. NRTIs background regimens will remain unchanged if possible. NRTIs background may include zidovudine/lamivudine, zidovudine plus ddI, ddI plus lamivudine, tenofovir plus lamivudine, tenofovir/emtricitabine, zidovudine plus tenofovir. NRTI backbone could be switched or modified due to toxicity or intolerance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV/r
Description: All participants will be randomized to take ATV/r 200 mg/100 mg OD or ATV/r 300/100 mg OD. NRTIs background regimens will remain unchanged if possible. NRTIs background may include zidovudine/lamivudine, zidovudine plus ddI, ddI plus lamivudine, tenofovir plus lamivudine, tenofovir/emtricitabine, zidovudine plus tenofovir. NRTI backbone could be switched or modified due to toxicity or intolerance
Study: NCT04602897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: forced coughing
Description: The cough group patients were asked to cough a forced cough during different steps of IUD insertion
Study: NCT04294394

Intervention type: OTHER
Intervention: rhomboid block
Description: Rhombid block, on the other hand, is a method which make up analgesia by providing lokal anestethetic enjection between intercostal muscles and rhomboid muscles and blocks between t3- t9 levels

Intervention type: OTHER
Intervention: erector spinae block
Description: The Erector spinae plan block is a recently developed regional block method .Adminestering of lokal anesthetic between the transver proces and erector spinae muscles provides the dorsal and ventral branch blokades of regional spinal nerve and make up the analgesia.İt have a wide range usage such as surgery of thoracal and abdominal area

Intervention type: OTHER
Intervention: control
Description: For postoperative analgesia, all patients (including Rhomboid block and Erector spinae block) will be administered 100 mg tramadol and 1 gr paracetamol. No additional intervention other than this medical approach will be applied in the control group.
Study: NCT02142582

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: WHO ORS
Description: Participants will be randomized into one of the two groups. They will be provided with one of the two ORS solutions. Then, they will be followed for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Commercial ORS
Description: Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
Study: NCT02418975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low-calorie protein-based diet
Description: Patients will receive a homemade very low-calorie (\~5 kcal/kg of ideal body weight /day) protein-based formula (milk proteins; 1.2 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet
Description: Patients will receive a commercial balanced enteral formula (\~20 kcal/kg of ideal body weight /day; protein content, 1.0 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
Study: NCT02289989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oregano extract cream
Description: An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
Study: NCT03303586

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression Stockings
Description: We will use knee length, ready-made compression stockings at a pressure of 20-30mmHg at the ankle and if a good fit cannot be obtained, custom-made stockings will be ordered. Patients will be measured for compression stockings by a certified fitter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression Stockings
Description: We will use knee length, ready-made compression stockings at a pressure of 20-30mmHg at the ankle and if a good fit cannot be obtained, custom-made stockings will be ordered. Patients will be measured for compression stockings by a certified fitter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will not wearing compression stockings for two weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will not wearing compression stockings for two weeks.
Study: NCT02307513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets for oral administration
Study: NCT00754975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JACTAX LD DES
Description: Drug Eluting Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS™ Libertè™ DES
Description: Drug Eluting Stent
Study: NCT02712697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WM (Shentong Granules)
Description: Shentong Granules with Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hormone (prednisone)
Description: Oral prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone (prednisone)
Description: Oral prednisone
Study: NCT04885387

Intervention type: DEVICE
Group type: OTHER
Intervention: chest CT
Description: chest CT pectus deformities diagnostic

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device
Description: Magnetic Resonance Imaging and a low-cost portable three-dimensional scanning device pectus deformities diagnostic
Study: NCT03622203

Intervention type: DEVICE
Intervention: Biofreedom
Description: Use of Biofreedom in real life patients

Intervention type: DEVICE
Intervention: Biofreedom
Description: Use of Biofreedom in real life patients

Intervention type: DEVICE
Intervention: Biofreedom
Description: Use of Biofreedom in real life patients
Study: NCT02393924

Intervention type: OTHER
Intervention: No intervention
Study: NCT00251082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous combined estradiol and dydrogesterone
Description: 0.5 Mg Estradiol and 2.5 Mg Dydrogesterone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous combined estradiol and dydrogesterone
Description: 1 Mg Estradiol and 5 Mg Dydrogesterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01435096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN80927
Description: Administered over 30 minutes in the vein with a fixed infusion rate once every 3 weeks. Each patient could participate in a maximum of 10 continuous cycles, equivalent to 30 weeks treatment.
Study: NCT02835651

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palmitic acid
Description: Experimental products are enriched with C16:0

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stearic acid
Description: Experimental products are enriched with C18:0
Study: NCT03375632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Description: Oral daily dosing for 14 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Description: Oral daily dosing for 14 weeks
Study: NCT00548067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan/hydrochlorothiazide (HCTZ)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan/amlodipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine/hydrochlorothiazide(HCTZ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan/amlodipine/hydrochlorothiazide(HCTZ)
Study: NCT02936713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented milk product with probiotics (FMPP)
Description: 2 pots of 125g FMPP / day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented milk product with probiotics (FMPP)
Description: 2 pots of 125g FMPP / day
Study: NCT03603392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity program
Study: NCT03290560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human tissue kallikrein
Description: Recombinant human tissue kallikrein

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Phosphate buffered saline
Study: NCT03868241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coated devices
Description: Gold-silver-palladium coated devices (endotracheal tube, central venous catheter and urinary catheter) will be used whenever necessary. All three devices are required to be inserted as soon as possible after randomization and need for all three devices are the main inclusion criteria

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Devices without coating available at each participating intensive care unit
Study: NCT00986115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
Study: NCT04459559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tactile Cueing Device
Description: Each participant receives an individual training on how to use the Tactile Cueing Device and the set-up of the TCD will be done according to the results of a 10MWT and the participant's preferences. Gait assessments with an activated or deactivated TCD are executed using the Timed Up and Go test, the 2-Minute Waling test and a treadmill (C-Mill). Also a long-term test run of the TCD during one day is planned.
Study: NCT03846505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: A 40-IU dose of oxytocin will be self-administered 30 minutes prior to the start of each weekly ABCT session.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be self-administered 30 minutes prior to the start of each weekly ABCT session.
Study: NCT04362657

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computer Aided Diagnosis
Description: Computer Aided diagnosis is an environment-enhancing technology developed to aid humans to improve their accuracy, speed and confidence by providing live feedback during the procedure, on request, or after the procedure has been completed.
Study: NCT01885273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressurized irrigation method
Description: The pressurized irrigation device is modified from using a special Syringe, connected to Gomco's Vacuum/Pressure Pump Model 309 that generate steady irrigation stream at pressure between 4 to 15 psi that is recommended to be safe and effective pressure for wound cleansing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Swabbing wound cleansing method
Description: All patients in control group had wounds cleansed with swabbing technique using forceps and cotton wool (in sterile dressing pack)
Study: NCT02366936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tortle Midliner
Description: The Tortle Midliner is a breathable, knit beanie with two support rolls to help position the infant's head in midline while supine. It can also be worn sidelying or prone. The design includes Velcro adjustments and tabs for nasal cannula and feeding tubes. It is compatible with some ventilation devices, nasal CPAP, X-ray, and bilirubin shades. The beanie is designed to prevent dolichocephaly and provide passive stretch to cervical rotators if head preference has developed. It comes in three sizes and can fit preemies weighing 500 to 2500 g.
Study: NCT01042990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive Physical Activity
Description: Structured gait, balance, and progressive walking program performed in a group gym setting 3x/week for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive Physical Activity
Description: Structured gait, balance, and progressive walking program performed in a group gym setting 3x/week for 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive Physical Activity
Description: Structured gait, balance, and progressive walking program performed in a group gym setting 3x/week for 6 months
Study: NCT01280318

Intervention type: PROCEDURE
Group type: OTHER
Intervention: head and neck surgery
Description: Blood Sample of biomakers at 3 days, 5 weeks and 3 months after surgery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: head and neck surgery
Description: Blood Sample of biomakers at 3 days, 5 weeks and 3 months after surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: head and neck surgery
Description: Blood Sample of biomakers at 3 days, 5 weeks and 3 months after surgery.
Study: NCT02654093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Study: NCT02303223

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Study: NCT02654093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Study: NCT00904865

Intervention type: PROCEDURE
Group type: OTHER
Intervention: SPA cholecystectomy
Description: SPA cholecystectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy
Study: NCT01817582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lotemax
Description: Lotemax gel will be administered as per the dose and schedule specified in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lotemax
Description: Lotemax gel will be administered as per the dose and schedule specified in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restasis
Description: Restasis emulsion will be administered as per the dose and schedule specified in the arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis
Description: Restasis emulsion will be administered as per the dose and schedule specified in the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soothe® Lubricant Eye Drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soothe® Lubricant Eye Drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soothe® Lubricant Eye Drops
Study: NCT02345460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies